HIV-1 PROTEASE (V82F/I84V) DOUBLE MUTANT COMPLEXED WITH SD146 OF DUPONT PHARMACEUTICALS
收藏NIAID Data Ecosystem2026-05-01 收录
数据链接：
官方服务：
资源简介：
HIV-1 PROTEASE (V82F/I84V) DOUBLE MUTANT COMPLEXED WITH SD146 OF DUPONT PHARMACEUTICALS
应用场景：
创建时间：
2024-02-07
相关数据集
Crystal structure of the Myxococcus Xanthus hemagglutinin (MBHA)
Crystal structure of the Myxococcus Xanthus hemagglutinin (MBHA) Descriptor: Myxobacterial hemagglutinin Authors: Koharudin, L.M.I, Gronenborn, A.M. Deposit date: 2012-05-23 Release date: 2012-08-15 L
Protein Data Bank Japan2023-09-13 更新90
8-Modified-2′-Deoxyadenosine Analogues Induce Delayed Polymerization Arrest during HIV-1 Reverse Transcription
The occurrence of resistant viruses to any of the anti-HIV-1 compounds used in the current therapies against AIDS underlies the urge for the development of new drug targets and/or new drugs acting thr
NIAID Data Ecosystem40
Discovery of Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor for HIV‑1 Treatment and Pre-exposure Prophylaxis
The HIV capsid is essential to the virus lifecycle, making it a promising target for therapeutic intervention. In 2006, a screening campaign was initiated to identify small molecules capable of disrup
Figshare2025-10-01 更新20
DPC 817: a Cytidine Nucleoside Analog with Activity against Zidovudine- and Lamivudine-Resistant Viral Variants
Highly active antiretroviral therapy (HAART) is the standard treatment for infection with the human immunodeficiency virus (HIV). HAART regimens consist of protease inhibitors or nonnucleoside reverse
PubMed Central40
Design and Development of Highly Potent HIV‑1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants
Design, synthesis, and evaluation of a new class of exceptionally potent HIV-1 protease inhibitors are reported. Inhibitor 5 displayed superior antiviral activity and drug-resistance profiles. In fact
Figshare2017-04-18 更新30
